• 1
    Bolla M, Collette L, Blank L et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360: 103106
  • 2
    Denham JW, Steigler A, Lamb DS et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 2005; 6: 841850
  • 3
    Pilepich MV, Winter K, John MJ et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncl Biol Phys 2001; 50: 12431252
  • 4
    Pilepich MV, Winter K, Lawton CA et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma – long-term results of phase III RTOG 85-31. Int J Radiat Oncl Biol Phys 2005; 61: 12851290
  • 5
    D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2004; 292: 821827
  • 6
    Kuban DA, Tucker SL, Dong L et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncl Biol Phys 2008; 70: 6774
  • 7
    Zelefsky MJ, Pei X, Chou JF et al. Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes. Eur Urol 2011; 60: 11331139
  • 8
    Stock RG, Stone NN, Cesaretti JA, Rosenstein BS. Biologically effective dose values for prostate brachytherapy: effects on PSA failure and posttreatment biopsy results. Int J Radiat Oncl Biol Phys 2006; 64: 527533
  • 9
    Zelefsky MJ, Yamada Y, Pei X et al. Comparison of tumor control and toxicity outcomes of high-dose intensity-modulated radiotherapy and brachytherapy for patients with favorable risk prostate cancer. Urology 2011; 77: 986990
  • 10
    American Joint Committee on Cancer/American Cancer Society. In Beahrs OH , Henson DE , Hutter RVP , Kennedy BJ eds, Manual for Staging of Cancer, 4th edn. Philadelphia, PA: Lippincott, 1992
  • 11
    Stone NN, Stock RG. The effect of brachytherapy, external beam irradiation and hormonal therapy on prostate volume. J Urol 2007; 177: 925928
  • 12
    Lee LN, Stock RG, Stone NN. Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation. Int J Radiat Oncl Biol Phys 2002; 52: 444452
  • 13
    Hanks GE, Pajak TF, Porter A et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003; 21: 39723978
  • 14
    Stock RG, Cesaretti JA, Hall SJ, Stone NN. Outcomes for patients with high-grade prostate cancer treated with a combination of brachytherapy, external beam radiotherapy and hormonal therapy. BJU Int 2009; 104: 16311636
  • 15
    Stone NN, Potters L, Davis BJ et al. Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7–10 prostate cancer treated with permanent prostate brachytherapy. Int J Radiat Oncl Biol Phys 2009; 73: 341346
  • 16
    Roach M III, Hanks G, Thames H Jr et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncl Biol Phys 2006; 65: 965974
  • 17
    Laverdiere J, Gomez JL, Cusan L et al. Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncl Biol Phys 1997; 37: 247252
  • 18
    Zelefsky MJ, Leibel SA, Gaudin PB et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncl Biol Phys 1998; 41: 491500
  • 19
    Dearnaley DP, Sydes MR, Graham JD et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007; 8: 475487
  • 20
    Castle KO, Hoffman KE, Levy LB et al. Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era? Int J Radiat Oncol Biol Phys 2013; 85: 693699
  • 21
    Zumsteg ZS, Spratt DE, Pei X et al. Short-term androgen-deprivation therapy improves prostate cancer-specific mortality in intermediate-risk prostate cancer patients undergoing dose-escalated external beam radiation therapy. Int J Radiat Oncol Biol Phys 2013; 85: 10121017
  • 22
    Dattoli M, Wallner K, True L, Cash J, Sorace R. Long-term outcomes after treatment with brachytherapy and supplemental conformal radiation for prostate cancer patients having intermediate and high-risk features. Cancer 2007; 110: 551555
  • 23
    Merrick GS, Butler WM, Galbreath RW, Lief JH, Adamovich E. Does hormonal manipulation in conjunction with permanent interstitial brachytherapy, with or without supplemental external beam irradiation, improve the biochemical outcome for men with intermediate or high-risk prostate cancer? BJU Int 2003; 91: 2329
  • 24
    Martinez A, Galalae R, Gonzalez J, Mitchell C, Gustafson G, Kovacs G. No apparent benefit at 5 years from a course of neoadjuvant/concurrent androgen deprivation for patients with prostate cancer treated with a high total radiation dose. J Urol 2003; 170: 22962301
  • 25
    D'Amico AV, Moran BJ, Braccioforte MH et al. Risk of death from prostate cancer after brachytherapy alone or with radiation, androgen suppression therapy, or both in men with high-risk disease. J Clin Oncol 2009; 27: 39233928